Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.

Journal of neurology·2026
Same author

Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.

Journal of neurology·2026
Same author

Aging does not affect the relationship between OCT and clinical or MRI outcome measures.

Multiple sclerosis and related disorders·2026
Same author

Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Parallelism in neurodegenerative biomarker tests: hidden errors and the risk of misconduct.

Critical reviews in clinical laboratory sciences·2025
Same author

LegioTyper: Rapid typing of Legionella pneumophila serogroup 1 by flow-based chemiluminescence sandwich microarray immunoassay.

Analytical and bioanalytical chemistry·2025

Related Experiment Video

Updated: May 27, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.

M J Eikelenboom1, B M J Uitdehaag, A Petzold

  • 1Department of Neurology, MS Center Amsterdam, VU University Medical Center, Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

Multiple Sclerosis International
|November 19, 2011
PubMed
Summary

Neurofilament heavy chain (NfH) biomarkers in cerebrospinal fluid (CSF) and serum do not correlate in multiple sclerosis (MS). Peripheral nervous system involvement may influence serum NfH levels, impacting interpretation of central nervous system disease progression.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Related Experiment Videos

Last Updated: May 27, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings
10:46

Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

Published on: September 1, 2023

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Multiple Sclerosis Research

Background:

  • Disability in multiple sclerosis (MS) is linked to neuroaxonal degeneration.
  • A validated blood biomarker for neuroaxonal degeneration is crucial for MS management.
  • Neurofilaments heavy chain (NfH) are potential biomarkers for neuroaxonal damage.

Purpose of the Study:

  • To investigate the correlation between cerebrospinal fluid (CSF) and serum concentrations of NfH phosphoforms in MS patients.
  • To explore the utility of NfH biomarkers in predicting disability progression across different MS subtypes.
  • To assess the influence of potential peripheral nervous system (PNS) pathology on serum NfH levels.

Main Methods:

  • Cross-sectional (n=51) and longitudinal (n=34) study design.
  • Quantification of CSF and serum NfH-SMI34 and NfH-SMI35 levels at baseline.
  • Assessment of Expanded Disability Status Scale (EDSS) and disability progression over 3 years.

Main Results:

  • No significant correlation was found between serum and CSF NfH phosphoform levels in MS.
  • Baseline serum NfH-SMI34 levels were significantly higher in primary progressive MS (PPMS) and secondary progressive MS (SPMS) compared to relapsing-remitting MS (RRMS).
  • Higher serum NfH-SMI34 predicted progression in SPMS, while higher CSF NfH-SMI35 predicted progression in RRMS.

Conclusions:

  • Serum and CSF NfH levels are not directly correlated in MS, suggesting distinct origins or processing.
  • Neuroaxonal degeneration of the central nervous system (CNS) is likely the primary driver of progression in RRMS.
  • In PPMS/SPMS, peripheral nervous system (PNS) pathology may contribute to elevated serum NfH, complicating CNS disease interpretation.